Previously, serving as Vice President, Business Development at deCODE genetics, King helped lead the turnaround of that company, which was acquired by Amgen in 2012. King's professional life has focused on transforming innovation into value in the life sciences, both in corporate development and operational roles. She ran the business development functions at life sciences tools leader PerkinElmer, proteomics start-up BioScale, and the J. Craig Venter Institute. In the world of pharma/biotech R&D, King's experience has also been operational; she headed scientific and strategic operations globally at the Novartis Institutes for Biomedical Research. She received her PhD in molecular genetics from the University of Cambridge, and her AB Phi Beta Kappa in molecular biology from Princeton University.